Thrombectomy for Anterior Circulation Stroke Beyond 6 h from Time Last Known Well (AURORA): A Systematic Review and Individual Patient Data Meta-Analysis
Lancet 399:249-258, Jovin, T.G.,et al, 2022
Does My District Need a Mobile Stroke Unit?
NEJM 385:971-981,1043, Lees, K.R., 2021
Guidelines for the Early Management of Patients with Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke
Stroke 50:e344-e418, Powers, W.J.,et al, 2019
Primary Thrombectomy in tPA (Tissue-Type Plasminogen Activator) Eligible Stroke Patients with Proximal Intracranial Occlusions
Stroke 49:265-269, Fischer, U.,et al, 2018
2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke
Stroke 49:e46-e110, Powers, W.J.,et al, 2018
Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic STroke
Stroke 47:581-641, Demaerschalk, B.M.,et al, 2016
Stroke Outcomes with use of Antithrombotics within 24 hours after Recanalization Treatment
Neurol 87:996-1002, Jeong, H.G.,et al, 2016
2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients with Acute Ischemic Stroke Regarding Endovascular Treatment
Stroke 46:3021-3035, Powers, W.J.,et al, 2015
Endovascular Treatment for Acute Ischemic Stroke-Still Unproven
NEJM 368:952-955, Chimowitz,M., 2013
Thrombolysis for Ischemic Stroke Associated with Infective Endocarditis
Stroke 44:2917-2919, Asaithambi, G.,et al, 2013
Acute Stroke Imaging: What is Sufficient for Triage to Endovascular Therapies?
AJNR 33:790-792, Lev, M.H., 2012
Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:1158-1192, Saposnik,G.,et al, 2011
Diagnosis and management of transient ischaemic attack and ischaemic stroke in the acute phase
BMJ 342:d1938, McArthur, K.S.,et al, 2011
Intravenous Thrombolytic Therapy for Acute Ischemic Stroke
NEJM 364:22, Wechsler, L.R., 2011
Effects of Extending the Time Window of Thrombolysis to 4.5 Hours Observations in the Swedish Stroke Register (Riks-Stroke)
Stroke 42:2492-2497, Asplund, K.,et al, 2011
Expansion of the Time Window for Treatment of Acute Ischemic Stroke with Intravenous Tissue Plasminogen Activator: A Science Advisory from the American Heart Association/American Stroke Association
Stroke 40:2945-2948, del Zoppo,G.J.,et al, 2009
Stroke Therapy Academic Industry Roundtable (STAIR) Recommendations for Extended Window Acute Stroke Therapy Trials
Stroke 40:2594-2600, Saver,J.L.,et al, 2009
Treatment of Childhood Arterial Ischemic Stroke
Ann Neurol 63:679-696, Bernard,T.J.,et al, 2008
Review of Tissue Plasminogen Activator, Ischemic Stroke, and Potential Legal Issues
Arch Neurol 65:1429-1433, Liang,B.A.,et al, 2008
Established Treatments for Acute Ischaemic Stroke
Lancet 369:319-330, Khaja,A.M. &Grotta,J.C., 2007
Thrombolysis With Alteplase for Acute Ischaemic Stroke in the Safe Implementation of Thrombolysis in stroke-Monitoring Study (SITS-MOST): An Observational Study
Lancet 369:275-282,249, Wahlgren,N.,et al, 2007
Guidelines for the Early Management of Adults With Ischemic Stroke
Stroke 38:1655-1711, Adams,H.P.,et al, 2007
Magnetic Resonance Perfusion Diffusion Mismatch and Thrombolysis in Acute Ischaemic Stroke: A Systematic Review of the Evidence to Date
JNNP 78:485-491,443, Kane,I.,et al, 2007
Acute Ischemic Stroke
NEJM 357:572-529, Bart van der Worp,H. &van Gijn,J., 2007
Guidelines for the Early Management of Patients with Ischemic Stroke
Stroke 36:916-921, Adams,H.,et al, 2005
Cuahoga County Operation Stroke Speed of Emergency Department Evaluation and Compliance with National Institutes of Neurological Disorders and Stroke Time Targets
Stroke 34:994-998, Katzan,I.L.,et al, 2003
Community Use of Intravenous Tissue Plasminogen Activator for Acute Stroke
Stroke 32:861-865, Katzan,I.L.,et al, 2001
Intravenous Tissue-Type Plasminogen Activator Therapy for Ischemic Stroke
Arch Neurol 58:2009-2013, Grotta,J.C.,et al, 2001
Acute Stroke Care in Non-urban Emergency Departments
Neurol 57:2006-2012, Burgin,W.S.,et al, 2001
Diagnosis and Treatment of Ischemic Stroke
Am J Med 106:211-221, Alberts,M.J., 1999
Initial Clinical Experience with IV Tissue Plasminogen Activator for Acute Ischemic Stroke:A Multicenter Survey
Neurol 53:424-427, Tanne,D.,et al, 1999
Thrombolytic Therapy in Acute Stroke
Arch Neurol 55:155-157, Horowitz,S.H., 1998
Intravenous Thrombolysis for Acute Stroke
Neurol 49:14-29, Lyden,P.D.,et al, 1997
Systematic Review of Evidence on Thrombolytic Therapy for Acute Ischaemic Stroke
Lancet 350:607-614, Wardlaw,J.M.,et al, 1997
Generalized Efficacy of t-PA for Acute Stroke
The NINDS t-PA Stroke Study Group, Stroke 28:2119-21251997., , 1997
Thrombolytic Therapy for Acute Ischemic Stroke-Summary Statement
Report of the Quality Standards Subcommittee of the AAN, Neurol 47:835-8391996., , 1996
Guidelines for the Management of Patients with Acute Ischemic Stroke
Stroke 25:1901-1914, Adams,H.P.,et al, 1994
Subarachnoid Hemorrhage
NEJM 377:257-266, Lawton, M.T. & Vates, G.E., 2017
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Use of Marijuana: Effect on Brain Health: A Scientific Statement from the American Heart Association
Stroke 53:e176-e187, Fernando, T.,et al, 2022
Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017
Disparities and Guideline Adherence in Drugs of Abuse Screening in Intracerebral Hemorrhage
Neurol 88:252-258, Tomoehlen, L.M.,et al, 2017
Migraine
NEJM 377:553-561, Charles, A., 2017
International Consensus Guidance for Management of Myasthenia Gravis
Neurol 87:419-425, Sanders, D.B.,et al, 2016
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Variability of Brain Death Determination Guidelines in Leading US Neurologic Institutions
Neurol 70:284-289,252, Greer,D.M.,et al, 2008
Position Statement Regarding the Use of Embryonic and Adult Human Stem Cells in Biomedical Research
Neurol 64:1679-1680,1675, American academy of Neurology and American Neurological Association, 2005
Practice Parameter:Immunotherapy for Guillain-Barre Syndrome, Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 61:736-740, Hughes,R.A.C.,et al, 2003